Rheumatoid Arthritis (RA) Clinical Trial
— BIOSAFEOfficial title:
Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics
Verified date | December 2018 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background : Inflammatory arthritis (rheumatoid arthritis (RA) or spondyloarthritis (SpA) are
painful chronic diseases which impair quality of life and work capacity. Biologics are very
effective and widely used therapies. However, they are known to entail risks, particularly of
infections. The risk of severe infections is of 5%/patient-year with a maximum during the
first six month after the initiation of the first biologic therapy.
Patient education (PE) is recommended for the management of chronic diseases. In the case of
biologics, PE aims to help patients to learn specific skills particularly on safety issues,
e.g stopping the biologic treatment in case of fever or surgery. Safety skills are assessed
by the validated BIOSECURE questionnaire. PE seems efficient for safety skills in a few
non-randomized studies. In 2010 a national cross sectional survey on 677 patients showed that
the risk of incorrect answers in the BIOSECURE questionnaire was 4 times lower among patients
who had benefited from an education by a nurse or other kind of educational process (OR =3,8
IC95% :[1,68-8,8].
Aims and Hypothesis: this trial aims to investigate the effects of a nurse-led
self-management education face to face intervention on safety skills of patients with
arthritis treated par sub cutaneous biologics. Our hypothesis is that the intervention group
will report better skills at the 6 months follow up compared to usual care i.e information by
the rheumatologist in current consultation.
Methods : multicentric randomized controlled open trial with blinded assessment of the
primary outcome. The intervention group will have a nurse education consultation at M 0 and
M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients'
health beliefs and educational needs, focusing on safety skills, self-injections and
motivation. The control group will have usual care by the rheumatologist.
Status | Completed |
Enrollment | 129 |
Est. completion date | November 26, 2018 |
Est. primary completion date | November 26, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age 18-75 years - Patients with RA ( ACR/EULAR criteria), axial or peripheral Spondyloarthritis (ASAS criteria), patients who are eligible for a Sub cutaneous biologic treatment according to the French recommendations of care - patients naïve from biologics. - Patients benefiting from French Social Security insurance. Exclusion Criteria: - Patients unable to speak or read French language, - Patients unable to complete a questionnaire or meet with the trial obligations - Patients suffering from severe cognitive or psychiatric dysfunction |
Country | Name | City | State |
---|---|---|---|
France | Service de Rhumatologie Hôpital Saint Antoine | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety knowledge and skills towards biologic treatment | score of the BIOSECURE Questionnaire, a 54 item questionnaire including competences to deal with fever, infections, vaccination, and other daily life situations | 6 months | |
Secondary | Quality of life | SF12 | 6 months | |
Secondary | Severe infections rate | Severe infections will be defined as infections requiring Intravenous antibiotics or hospitalization. | 6 months | |
Secondary | Coping and psychological well-being (RAID Rheumatoid arthritis Impact of disease score) | VASs coping and psychological well-being from the RAID Rheumatoid arthritis Impact of disease score | 6 months | |
Secondary | Coping and psychological well-being (AHI Arthritis helplessness index) | VASs coping and psychological well-being from AHI Arthritis helplessness index | 6 months | |
Secondary | Disease activity (DAS 28) | DAS 28 (Disease Activity index) for the patients with RA | 6 months | |
Secondary | Disease activity (ASDAS) | ASDAS (Ankylosing spondylarthritis Disease activity score) for the patients with SpA | 6 months | |
Secondary | Disease activity (BASDAI) | BASDAI (Bath Ankylosing spondylarthritis Disease activity Index) for the patients with SpA | 6 months | |
Secondary | Beliefs about biologics | BMQ Beliefs about medicine questionnaire (specific) | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047341 -
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
|
Phase 1 | |
Withdrawn |
NCT02786563 -
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
|
||
Completed |
NCT03257852 -
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
|
Phase 2 | |
Completed |
NCT03660059 -
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
|
Phase 3 | |
Recruiting |
NCT03971253 -
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
|
||
Not yet recruiting |
NCT05486715 -
Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
|
||
Completed |
NCT03682705 -
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
Active, not recruiting |
NCT04574492 -
A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
|
||
Active, not recruiting |
NCT02805010 -
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously
|
Phase 1 | |
Completed |
NCT01871961 -
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
|
Phase 1 | |
Completed |
NCT04497597 -
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
|
||
Terminated |
NCT02775656 -
UCB Cimzia Pregnancy Follow-up Study
|
||
Completed |
NCT01173120 -
Methotrexate - Inadequate Response Device Sub-Study
|
Phase 3 | |
Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
Completed |
NCT03086343 -
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
|
Phase 3 | |
Terminated |
NCT01569152 -
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
|
Phase 2 | |
Completed |
NCT02105129 -
A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
|
Phase 1 | |
Completed |
NCT01577563 -
Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
|
N/A | |
Completed |
NCT01618968 -
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
|
Phase 2 | |
Completed |
NCT01618955 -
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
|
Phase 2 |